Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 3 ($0.04) and last traded at GBX 3.01 ($0.04), with a volume of 869168 shares trading hands. The stock had previously closed at GBX 3.24 ($0.04).
Analyst Ratings Changes
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
Read Our Latest Stock Report on Poolbeg Pharma
Poolbeg Pharma Stock Up 3.2 %
About Poolbeg Pharma
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Read More
- Five stocks we like better than Poolbeg Pharma
- How to Use the MarketBeat Dividend Calculator
- Is Myers Industries Poised for a Breakout?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- CD Calculator: Certificate of Deposit Calculator
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
